Compare Merck & Co., Inc. (MRK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Orion Office REIT Inc — how do they compare? Merck & Co., Inc. trades at $132.38 (market cap $321.77B), while Orion Office REIT Inc trades at $2.76 (market cap $158.01M). The key difference: Merck & Co., Inc. is far larger — about 2036.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| MRK | ONL | |
|---|---|---|
Market Cap | $321.77B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $131.84 | $3.04 |
52-Week Low | $77.60 | $1.93 |
Enterprise Value | $368.53B | $574.95M |
Dividend Yield | 2.61% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
ONL trades at $2.80, up 1.82% with a bullish technical signal. The company reported mixed Q2 2026 results with an EPS beat but faces fundamental challenges including declining revenue and negative net income margins. Analyst consensus is split 50/50 between Buy and Hold ratings. Recent news highlights strategic review progress and portfolio repositioning efforts.
Outlook remains cautious due to persistent losses and revenue decline, though low P/B ratio and dividend payments offer some value. Key risks include continued negative profitability and high debt levels. The stock presents speculative value for investors tolerant of turnaround execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
